Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Inotuzumab Ozogamicin

Criteria

Inclusion Criteria:

• Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit

• At the expanded cohort, part 2 of the study, subjects must have one of the following:

• Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy

• Diffuse large B-cell lymphoma

• Age 18 years or older

Exclusion Criteria:

• Candidate for potentially curative therapies in the opinion of the investigator

• Chronic lymphocytic leukemia

• Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma